No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Aarti Pharmalabs Limited, headquartered in Mumbai, India, and established in 2019 (originally Aarti Organics Limited), primarily focuses on the production and global distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. These vital compounds are utilized in medications across a wide range of therapeutic categories, including treatments for hypertension, asthma, cancer, central nervous system conditions, dermatological issues, congestion, cardiovascular diseases, thalassemia, pain management, diabetes, and ophthalmic disorders. Beyond its core offerings, the company is also involved in creating novel chemical entities (NCEs), regulatory starting materials (RSMs), basic and key starting materials (KSMs), essential building blocks, xanthine derivatives, and related chemical products. Moreover, Aarti Pharmalabs provides comprehensive contract development and manufacturing (CDMO) solutions. These services, covering drug substance projects like NCEs, APIs, RSMs, and intermediates, are extended to innovative pharmaceutical and biotechnology companies globally.
www.aartipharmalabs.comNo one on the platform currently holds AARTIPHARM.BO.
No tracked institution reports a position in AARTIPHARM.BO as of their last filing.
No one on the platform has traded AARTIPHARM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.8% | 9.9% | — | — | — | |
| Rev. Growth % | -14.0% | |||||
| Profit Margin % | 9.6% | 10.9% | ||||
| Free Cash Flow Margin % | -10.2% | -4.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $20.6B | — | $17.80 | $17.80–$17.80 | — | 1 |
| 2028 | $23.7B | +14.8% | $25.50 | $25.50–$25.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited | $349.65 | +2.40% | $56.9B | — |
| KOVAI.BOKovai Medical Center and Hospital Limited | $6014.60 | -3.29% | $65.8B | — |
| MARKSANS.BOMarksans Pharma Limited | $312.40 | -4.84% | $141.6B | — |
| MARKSANS.NSMarksans Pharma Limited | $312.85 | -5.02% | $141.8B | — |
| SHILPAMED.NSShilpa Medicare Limited | $911.90 | -5.12% | $178.4B | — |
Source: Financial Modeling Prep · peers by sector/industry